Day: August 7, 2024

Vishay Intertechnology Reports Second Quarter 2024 Results

MALVERN, Pa., Aug. 07, 2024 (GLOBE NEWSWIRE) — Vishay Intertechnology, Inc., (NYSE: VSH), one of the world’s largest manufacturers of discrete semiconductors and passive electronic components, today announced results for the fiscal second quarter ended June 29, 2024. Highlights 2Q 2024 revenues of $741.2 million Gross margin was 22.0% and included the negative impact of approximately 170 basis points related to the addition of Newport EPS of $0.17 2Q 2024 book-to-bill of 0.86 with book-to-bill of 0.82 for semiconductors and 0.90 for passive components Backlog at quarter end was 4.6 months “During the second quarter, we executed well on our Vishay 3.0 strategic plan, deepening our customer engagements supported by capacity that has landed and that we will continue to expand, and advancing our silicon carbide strategy as...

Continue reading

Ocular Therapeutix™ Reports Second Quarter 2024 Results

SOL-R AXPAXLI™ Repeat Dosing Study in Wet AMD Acceptable to FDA as Registrational Trial Enrollment in SOL-1 Continues to Accelerate and SOL-R Actively Enrolling Patients Cash Balance of $459.7M as of June 30, 2024, Expected to Fund Operations into 2028 Ocular Will Host a Q2 2024 Conference Call and Webcast Today, August 7th, at 8:00 AM ET BEDFORD, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) — Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today reported financial results for the second quarter ended June 30, 2024 and provided recent business highlights, including an update on the Phase 3 AXPAXLI™ (axitinib intravitreal...

Continue reading

Brookfield Asset Management Announces Strong Second Quarter

Assets Under Management Now Approximately $1 Trillion $68 Billion of Capital Raised in the Quarter Annualized FRE and DE Grew 11% and 12% to $2.5 Billion and $2.4 Billion BROOKFIELD, NEWS, Aug. 07, 2024 (GLOBE NEWSWIRE) — Brookfield Asset Management Ltd. (NYSE: BAM, TSX: BAM) today announced financial results for the quarter ended June 30, 2024. Connor Teskey, President of Brookfield Asset Management stated, “We had another strong quarter, which included $68 billion of capital raised. There is strong momentum in our Credit business, providing solutions to our partners globally. We also continue to see unprecedented opportunities in our Renewable Power and Transition business, as evidenced by the recent partnership with Microsoft and our agreement to acquire Neoen, one of the world’s leading renewable power operators. With one of...

Continue reading

Vertex Acquires ecosio To Accelerate Global E-Invoicing Compliance

Delivering a Seamlessly Connected Global Platform to Manage Continuous Compliance KING OF PRUSSIA, Pa., Aug. 07, 2024 (GLOBE NEWSWIRE) — Vertex, Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), a global provider of tax technology solutions, today announced the acquisition of ecosio, a leading B2B integration provider specializing in electronic data interchange (EDI) and e-invoicing. The closing is pending customary Austrian regulatory approval.    The acquisition advances a shared vision to accelerate global commerce and deliver a single, scalable platform for automating business transactions and managing indirect tax reporting and e-invoicing compliance. With the increasing prevalence of real-time and near real-time digital tax reporting mandates, e-invoicing is rapidly evolving into a crucial requirement for businesses operating...

Continue reading

Vertex Announces Second Quarter 2024 Financial Results

KING OF PRUSSIA, Pa., Aug. 07, 2024 (GLOBE NEWSWIRE) — Vertex, Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), a leading global provider of indirect tax solutions, today announced financial results for its second quarter ended June 30, 2024. “The second quarter financial results demonstrate the true earnings power of the Vertex business model,” stated David DeStefano, Vertex’s President, Chief Executive Officer and Chairperson of the Board. “We were GAAP earnings positive for the third quarter in a row, generated the highest level of quarterly cash provided by operating activities and free cash flow in our 46-year history and delivered our highest Adjusted EBITDA margin since we became a public company over four years ago.” DeStefano continued, “These are strong financial results, but we are just getting started. Several strategic...

Continue reading

Avista Corp. Reports Financial Results for the Second Quarter of 2024

Year-to-date consolidated earnings reflect strength of core utility operations Confirming consolidated earnings guidance of $2.36 to $2.56 per diluted share Continued investment in system improved reliability during recent heat wave SPOKANE, Wash., Aug. 07, 2024 (GLOBE NEWSWIRE) — Avista Corp. (NYSE: AVA) today announced financial results for the second quarter of 2024. Net income and earnings per diluted share for the second quarter and year-to-date 2024 compared to the same periods in 2023 are presented in the table below (dollars in thousands, except per-share data):     Second Quarter     Year-to-Date     2024     2023     2024     2023   Net Income (Loss) by Business Segment:                       Avista Utilities $ 23,935     $ 18,810     $ 91,443     $ 70,437   AEL&P   1,109       1,359       5,020       5,401   Other   (2,186 )     (2,685 )     (2,110 )     (3,509 ) Total...

Continue reading

SpringWorks Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

– Achieved $40.2 million in OGSIVEO® (nirogacestat) net product revenue in the second quarter – – Completed submission of NDA to the FDA for mirdametinib for the treatment of children and adults with NF1-PN – – Presented Phase 2b ReNeu trial results and additional analyses from Phase 3 DeFi trial at the 2024 ASCO Annual Meeting – – Initiated Phase 1a trial of SW-682 in patients with Hippo mutant solid tumors – STAMFORD, Conn., Aug. 07, 2024 (GLOBE NEWSWIRE) — SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today reported financial results for the second quarter of 2024 and provided an update on recent company developments. “We are very pleased with the continued strong momentum of our U.S. launch of OGSIVEO for adults with desmoid tumors....

Continue reading

Liquidia Corporation Reports Second Quarter 2024 Financial Results and Provides Corporate Update

MORRISVILLE, N.C., Aug. 07, 2024 (GLOBE NEWSWIRE) — Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today reported financial results for the second quarter ended June 30, 2024. The company will host a webcast at 8:30 a.m. ET on August 7, 2024 to discuss the financial results and provide a corporate update. Dr. Roger Jeffs, Liquidia’s Chief Executive Officer, said: “We continue to face no legal impediments for the FDA approval of YUTREPIA for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), and our commercial team stands ready to launch YUTREPIA contingent on the FDA’s final approval. If approved, we firmly believe that the ease of administration and...

Continue reading

Astec Reports Second Quarter 2024 Results

Second Quarter 2024 Overview (all comparisons are made to the corresponding prior year second quarter unless otherwise specified): Net sales of $345.5 million decreased 1.3% from the record sales in the prior year. Implied orders increased 5.9% sequentially from the first quarter. Inventory initiatives drove $28.7 million sequential reduction from the first quarter. Diluted EPS of $(0.61), which included an $0.89 per share impact related to goodwill impairment, compared to $0.58; Adjusted EPS of $0.61 compared to $0.87. Backlog of $531.1 million as of June 30, 2024. Federal highway bill spending in the early stages of deployment, with only ~ 20% funds disbursed and 38% committed. Total state budgets are up 12% year-over-year in fiscal year 2024 following an 11% increase in fiscal year 2023. CHATTANOOGA, Tenn., Aug. 07, 2024 (GLOBE...

Continue reading

Brink’s Announces Strong Second-Quarter Results

Record Second-Quarter revenue with growth of 3% Organic revenue growth of 14%, including accelerating AMS/DRS organic growth of 26%GAAP net income up 44% to $46M and adjusted EBITDA up 16% to $226MGAAP EPS up 51% to $1.03 and non-GAAP EPS up 31% to $1.67Repurchased over 722k shares year-to-date at average price of $91.02 per share RICHMOND, Va., Aug. 07, 2024 (GLOBE NEWSWIRE) — The Brink’s Company (NYSE:BCO), a leading global provider of cash and valuables management, digital retail solutions (DRS), and ATM managed services (AMS), today announced second-quarter results. Mark Eubanks, president and CEO, said: “Our strong second-quarter was highlighted by continued progress on our strategic objectives to grow AMS and DRS revenue, expand profit margins, and return excess cash to shareholders. Organic growth in AMS and DRS accelerated...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.